Kaposi sarcoma associated with rituximab-based cytotoxic therapy
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.1, pp.220-223, 2020 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 26 Issue: 1
- Publication Date: 2020
- Doi Number: 10.1177/1078155219835592
- Journal Name: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
- Page Numbers: pp.220-223
- Keywords: Rituximab, Kaposi sarcoma, lymphoma, HHV-8
- Inonu University Affiliated: Yes
Abstract
Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disease, mostly observed in immune compromised patients. KS is mostly encountered in HIV-positive or organ transplant patients. The drugs causing immunosuppression have also been associated with KS. Here, we present a KS experience associated with rituximab-based therapy.